Soft tissue tumors represent a very heterogeneous tumor group and are basically divided into two main groups as benign and malignant soft tissue tumors. Soft tissue sarcomas (STSs) are very rare, accounting for less than 1% of all malignant tumors. These sarcomas are often misdiagnosed as a benign soft tissue tumor and often result in inadequate management and unplanned resections. Definitive diagnosis of soft tissue tumors and differential diagnosis from other tumors are made based on histopathological findings, but routine biopsy is not feasible in all soft tissue lesions in the clinical practice. However, the rarity of soft tissue tumors and their overlapping radiological appearance make an accurate differential diagnosis difficult.

**Objectives:** In this study, we aimed to investigate the contribution of systemic inflammatory biomarkers to the diagnosis and to examine the relationship between cardiac parameters and malignancy in patients with extremity soft tissue sarcomas (STSs).

**Patients and methods:** Between January 2011 and December 2020, a total of 256 patients (155 males, 101 females; median age: 50 years; range, 18 to 87 years) who were diagnosed with benign and malignant soft tissue tumors were retrospectively analyzed. The control group consisted of a total of 150 age- and sex-matched healthy individuals (83 males, 67 females; median age: 52 years; range 19 to 76 years) with complete blood count analysis and having no STS. Demographic characteristics, laboratory parameters, and echocardiographic data of the patients were obtained from the hospital database. The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were calculated.

**Results:** Of a total of 256 patients included, 99 were diagnosed with benign tumors and 157 with malignant tumors. Lipoma was observed with the highest frequency of 40.4% among benign tumors, while malignant mesenchymal tumor (35.0%) was the most common tumor in the malignant group. There was no significant difference between the control and benign groups (p=0.198 and p=0.553, respectively), while the NLR and PLR of the malignant group were higher than both the control and benign groups, indicating a statistical significance (p<0.001). Total cholesterol, albumin, and ejection fraction (EF) levels of patients in the malignant group were significantly lower than the benign group (p=0.01, p<0.001, and p=0.046, respectively). According to the receiver operating characteristic curve, a cut-off value of 2.17 for NLR (sensitivity=64.1%, specificity=72%) and a cut-off value of 138.2 for PLR (sensitivity=60.9%, specificity=60.7%) were determined to distinguish malignant patients from healthy individuals. To distinguish malignant patients from the benign group, the cut-off values of NLR and PLR were 2.24 (sensitivity=62.8%, specificity=67.7%) and 137.9 (sensitivity=61%, specificity= 59.6%), respectively.

**Conclusion:** Our study results suggest that NLR and PLR can be used as diagnostic markers in malignant soft tissue tumors located in the extremities. In addition, total cholesterol, albumin, and EF values are lower than normal in malignant soft tissue tumors.

**Keywords:** Diagnosis, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, soft tissue sarcoma, soft tissue tumor.
Certain markers, such as C-reactive protein and D-dimer in blood tests, have been previously described to differentiate benign soft tissue tumors and STSs. However, these markers are useful, but not definitive. It is clear that generalizable and reliable parameters are needed in all soft tissue tumors, but despite many studies, specific blood markers for soft tissue tumors are still not available.

In recent years, there is a growing number of evidence showing that systemic inflammatory response (SIR) plays a critical role in cancer development. The components of SIR, neutrophils, lymphocytes and platelets, are considered to participate in the proliferation and migration of tumor cells. Two recent studies have shown that representative indices derived from inflammatory cells, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), are prognostic in STSs. However, to the best of our knowledge, there is no study investigating their effects in the differential diagnosis of soft tissue tumors located in the extremities. In addition, data on cardiac

| TABLE I |
|----------|
| Localization and type of tumors |
| Characteristic | Benign (n=99) | Malign (n=157) |
| Side | n | % | n | % |
| Right | 54 | 54.5 | 96 | 61.1 |
| Left | 45 | 45.5 | 61 | 38.9 |
| Histopathology | | | | |
| Lipoma | 40 | 40.4 | - | - |
| Schwannoma | 7 | 7.1 | - | - |
| Hemangioma-AV malformation | 15 | 15.2 | - | - |
| Ganglion cyst | 16 | 16.2 | - | - |
| Fibroma | 13 | 13.1 | - | - |
| TSGCT | 5 | 5.1 | - | - |
| Pilomatrixoma | 3 | 3 | - | - |
| Angiosarcoma | - | - | 3 | 1.9 |
| Fibrosarcoma | - | - | 10 | 6.4 |
| Synovial sarcoma | - | 23 | 14.6 |
| MMT | - | 55 | 35 |
| Pleomorphic sarcoma | - | 18 | 11.5 |
| MPNST | - | 3 | 1.9 |
| Leiomyosarcoma | - | 6 | 3.8 |
| Liposarcoma | - | 36 | 22.9 |
| Rhabdomyosarcoma | - | 3 | 1.9 |
| Localization | | | | |
| Hand-wrist | 20 | 20.2 | 0 | 0 |
| Forearm | 3 | 3 | 5 | 3.2 |
| Elbow | 3 | 3 | 4 | 2.5 |
| Arm | 9 | 9.1 | 13 | 8.3 |
| Axilla | 0 | 0 | 1 | 0.6 |
| Shoulder | 11 | 11.1 | 10 | 6.4 |
| Back | 1 | 1 | 2 | 1.3 |
| Gluteal region | 1 | 1 | 4 | 2.5 |
| Thigh | 15 | 15.2 | 79 | 50.3 |
| Knee | 3 | 3 | 4 | 2.5 |
| Popliteal region | 2 | 2 | 3 | 1.9 |
| Cruris | 11 | 11.1 | 28 | 17.8 |
| Foot-ankle | 20 | 20.2 | 4 | 2.5 |

AV: Arteriovenous; TSGCT: Tenosynovial giant cell tumor; MMT: Malignant mesenchymal tumor; MPNST: Malignant peripheral nerve sheath tumor.
function values and the status of lipid profile in soft tissue tumors are quite limited. In the present study, we, therefore, aimed to examine the effects of NLR and PLR in the detection of soft tissue tumors in the extremity and in the differential diagnosis of benign and malignant tumors, and to analyze cardiac markers in the presence of tumors.

PATIENTS AND METHODS

This single-center, retrospective, case-control study was conducted at University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Orthopedics and Traumatology outpatient clinic between January 2011 and December 2020. A total of 256 patients (155 males, 101 females; median age: 50 years; range, 18 to 87 years) who were diagnosed with benign and malignant soft tissue tumors were included in the study. Data including demographic and clinical data of the patients, histopathological diagnosis of the tumor, tumor location, pre-treatment complete blood count, serum albumin level, lipid profile, and baseline echocardiographic findings were recorded.

The control group consisted of a total of 150 age- and sex-matched healthy individuals (83 males, 67 females; median age: 52 years; range 19 to 76 years) who were admitted to the Orthopedics and Traumatology outpatient clinic of the study center. The control group had complete blood count analysis who were admitted for infectious diseases, trauma, fracture or reasons other than tumor. Those with incomplete data, having high C-reactive protein or procalcitonin values were excluded from the study. The NLR and PLR were calculated by dividing the absolute neutrophil and platelet counts by the absolute lymphocyte count, respectively. A written informed consent was obtained from each participant. The study protocol was approved by the University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Health Implementation and Research Center Ethic Board of Clinical Research (Date/No: 2020-07/732). The study was conducted in accordance with the principles of the Declaration of Helsinki.

Statistical analysis

Statistical analysis was performed using the IBM SPSS for Windows version 22.0 (IBM Corp., Armonk, NY, USA). Descriptive data were presented in mean ± standard deviation (SD) or median (min-max) for continuous variables and in number and frequency for categorical variables. Normal distribution for

| TABLE II | Evaluation of case groups and controls (n=406) |
|----------------------|-------------------------------|----------------------|
|                      | Controls (G1) (n=150) | Benign (G2) (n=99) | Malign (G3) (n=157) |
|----------------------|----------------------|----------------------|----------------------|
| n                    | %                   | Median              | Min-Max              | %                   | Median              | Min-Max              | %                   | Median              | Min-Max              | %                   | Median              |
| Age (year)           |                      | 52                  | 19-76                | 44                  | 60                  | 18-71                | 51                  | 18-87                | 0.104               | 0.096               | 0.002               | 0.988               | 0.002               | 0.988               |
| Sex                  |                      |                      |                      | Male                | 83                  | 55.3                 | 60.6                 | 60                   | 0.410               | 0.240               | 0.240               | 0.240               | 0.240               | 0.240               |
|                      |                      |                      |                      | Female              | 67                  | 44.7                 | 39.4                 | 39                   | 0.410               | 0.240               | 0.240               | 0.240               | 0.240               | 0.240               |
| Hb (mg/dL)           |                      | 10.6                 | 7.7-13.9             | 6.9                 | 9.3                 | 5.5-17                | 0.001                | 0.001                | 0.001               | 0.001               | 0.001               | 0.001               | 0.001               | 0.001               |
| WBC                  |                      | 6.3                  | 3.6-10.3             | 6.9                 | 9.3                 | 5.5-17                | 0.001                | 0.001                | 0.001               | 0.001               | 0.001               | 0.001               | 0.001               | 0.001               |
| Neutrophil           |                      | 3.6                  | 2.8-8.5              | 3.9                 | 2.1                 | 1.9                   | 0.007                | 0.007                | 0.007               | 0.007               | 0.007               | 0.007               | 0.007               | 0.007               |
| Lymphocyte           |                      | 2                    | 0.9-3.7              | 0.9-3.7             | 0.9-3.7             | 0.9-3.7              | 0.001                | 0.001                | 0.001               | 0.001               | 0.001               | 0.001               | 0.001               | 0.001               |
| Monocyte             |                      | 0.4                  | 0.2-1.2              | 0.2-1.2             | 0.2-1.2             | 0.2-1.2              | 0.001                | 0.001                | 0.001               | 0.001               | 0.001               | 0.001               | 0.001               | 0.001               |
| PLT                  |                      | 253                  | 157-487              | 271                 | 147-565             | 278                   | 0.001                | 0.001                | 0.001               | 0.001               | 0.001               | 0.001               | 0.001               | 0.001               |
| NLR                  |                      | 1.81                 | 0.11-9.3             | 1.99                | 0.11-9.3            | 0.11-9.3             | 0.001                | 0.001                | 0.001               | 0.001               | 0.001               | 0.001               | 0.001               | 0.001               |
| PLR                  |                      | 123.9                | 637-2881             | 128.1               | 509-3897            | 513                   | 0.001                | 0.001                | 0.001               | 0.001               | 0.001               | 0.001               | 0.001               | 0.001               |

Hb: Hemoglobin; WBC: White blood cell; PLT: Platelet; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; * Mann-Whitney U test; ** Chi-square test.
continuous variables was assessed with the visual (histograms and probability graphics) and analytic methods (Kolmogorov-Smirnov test). All the data did not fit the normal distribution. The Mann-Whitney U test was used for comparative analysis between the two independent groups. Comparison analyses for categorical variables between the separate groups were carried out using the chi-square test. The receiver operating characteristic (ROC) curve was used to identify the predictive value of the preoperative NLR and PLR for malignant-control distinction and malignant-benign distinction. The area under the ROC curve (AUC) results were considered excellent for AUC values between 0.9-1, good for AUC values between 0.8-0.9, fair for AUC values between 0.7-0.8, poor for AUC values between 0.6-0.7, and failed for AUC values between 0.5-0.6. The Youden index was used to determine the cut-off value calculated as max (sensitivity + specificity - 1). A p value of <0.05 was considered statistically significant.

RESULTS

Of a total of 256 patients included, 99 were diagnosed with benign tumors and 157 with malignant tumors. Lipoma was observed with the highest frequency of 40.4% among benign tumors, followed by ganglion cyst (16.2%), hemangioma-arteriovenous malformation (15.2%) and fibroma (13.1%). In the malignant group, the most common tumors are malignant mesenchymal tumor (35%), liposarcoma (22.9%), and synovial sarcoma (14.6%). Tumors in the benign group were mostly localized in the wrist (20.2%), ankle-foot (20.2%), and thigh (15.2%). In the malignant group, the tumors were mostly localized in the thigh (50.3%), crus (17.8%), and arm (8.3%) (Table I).

The median age of the malignant group was higher than the benign group (p=0.002). The sex distribution of the groups was similar (p=0.410, p=0.358, and p=0.988, respectively). Hemoglobin values of the control group were higher than both groups (p<0.001 and p<0.001, respectively). The white blood cell count of the control group was lower than both groups (p=0.001 and p<0.001, respectively). There was no significant difference in the NLR and PLR between the control and benign groups (p>0.05). While no significant difference was found between the control and benign groups (p=0.198 and p=0.553, respectively), the NLR and PLR of the malignant group were higher than both the control and benign groups, indicating a statistical significance (p<0.001) (Table II). In addition, lipid profiles and echocardiography parameters of patients in the benign and malignant groups are presented in Table III. Total cholesterol, albumin, and ejection fraction (EF) levels of patients in the malignant group were found to be significantly lower than the benign group (p=0.01, p<0.001, and p=0.046, respectively).

The ROC analysis, which was performed to investigate whether the NLR and PLR had a statistically significant cut-off value in the malignant-benign and malignant-healthy distinction, revealed that NLR and PLR had a diagnostic value with a statistically significant cut-off value (Table IV, Figures 1 and 2). The statistically significant cut-off value for NLR to distinguish malignant patients from healthy individuals was assessed with the visual (histograms and probability graphics) and analytic methods (Kolmogorov-Smirnov test). All the data did not fit the normal distribution. The Mann-Whitney U test was used for comparative analysis between the two independent groups. Comparison analyses for categorical variables between the separate groups were carried out using the chi-square test. The receiver operating characteristic (ROC) curve was used to identify the predictive value of the preoperative NLR and PLR for malignant-control distinction and malignant-benign distinction. The area under the ROC curve (AUC) results were considered excellent for AUC values between 0.9-1, good for AUC values between 0.8-0.9, fair for AUC values between 0.7-0.8, poor for AUC values between 0.6-0.7, and failed for AUC values between 0.5-0.6. The Youden index was used to determine the cut-off value calculated as max (sensitivity + specificity - 1). A p value of <0.05 was considered statistically significant.

RESULTS

Of a total of 256 patients included, 99 were diagnosed with benign tumors and 157 with malignant tumors. Lipoma was observed with the highest frequency of 40.4% among benign tumors, followed by ganglion cyst (16.2%), hemangioma-arteriovenous malformation (15.2%) and fibroma (13.1%). In the malignant group, the most common tumors are malignant mesenchymal tumor (35%), liposarcoma (22.9%), and synovial sarcoma (14.6%). Tumors in the benign group were mostly localized in the wrist (20.2%), ankle-foot (20.2%), and thigh (15.2%). In the malignant group, the tumors were mostly localized in the thigh (50.3%), crus (17.8%), and arm (8.3%) (Table I).

The median age of the malignant group was higher than the benign group (p=0.002). The sex distribution of the groups was similar (p=0.410, p=0.358, and p=0.988, respectively). Hemoglobin values of the control group were higher than both groups (p<0.001 and p<0.001, respectively). The white blood cell count of the control group was lower than both groups (p=0.001 and p<0.001, respectively). There was no significant difference in the NLR and PLR between the control and benign groups (p>0.05). While no significant difference was found between the control and benign groups (p=0.198 and p=0.553, respectively), the NLR and PLR of the malignant group were higher than both the control and benign groups, indicating a statistical significance (p<0.001) (Table II). In addition, lipid profiles and echocardiography parameters of patients in the benign and malignant groups are presented in Table III. Total cholesterol, albumin, and ejection fraction (EF) levels of patients in the malignant group were found to be significantly lower than the benign group (p=0.01, p<0.001, and p=0.046, respectively).

The ROC analysis, which was performed to investigate whether the NLR and PLR had a statistically significant cut-off value in the malignant-benign and malignant-healthy distinction, revealed that NLR and PLR had a diagnostic value with a statistically significant cut-off value (Table IV, Figures 1 and 2). The statistically significant cut-off value for NLR to distinguish malignant patients from healthy individuals

| TABLE III |
| Evaluation of lipid and echocardiography parameters values between case groups (n=256) |
| --- |
| **Benign (G2) (n=99)** | **Malign (G3) (n=157)** |
| **n % Median Min-Max IQR** | **n % Median Min-Max IQR** | **p** |
| Total cholesterol | 195 79-303 | 178 67-360 | 0.011* |
| HDL cholesterol | 37 14-129 | 36 16-54 | 0.499* |
| LDL cholesterol | 115.5 93-143 | 114 49-161 | 0.720* |
| TG | 123 45.2-165 | 123 42-374 | 0.434* |
| Albumin | 4.2 2.8-5.1 | 3.8 1.5-5 | <0.001* |
| EF (%) | 60 55-70 60-65 | 60 40-72 60-62 | 0.046* |
| IQR | 0.532** |
| MVR (84/126) | 3 3.6 | 8 6.3 | 0.247** |
| TVR (84/126) | 1 1.2 | 6 4.8 | 0.152** |
| AVR (84/126) | 0 0 | 4 3.2 | 1.000** |
| AVS (84/126) | 0 0 | 1 0.8 | |
| HDL: High-density lipoprotein; LDL: Low-density lipoprotein; TG: Triglyceride; EF: Ejection fraction; IQR: Interquartile range; MVR: Mitral valve replacement; TVR: Tricuspid valve replacement; AVR: Aort valve replacement; AVS: Aortic valve stenosis; * Mann-Whitney U test; ** Chi-square test |
Table IV

| Parameter                  | AUC       | 95% CI        | p      | Cut-off | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | + LHR | Max Youden Index |
|----------------------------|-----------|---------------|--------|---------|-----------------|-----------------|---------|---------|-------|------------------|
| Malignant-control distinction | 0.700     | 0.641-0.758   | <0.001 | ≥21.7   | 64.1            | 72              | 60.9    | 60.9    | 61.7  | 0.361            |
| NLR                        | 0.641     | 0.578-0.704   | <0.001 | ≥138.2  | 60.9            | 61.7            | 61.7    | 61.7    | 61.7  | 0.216            |
| PLR                        | 0.670     | 0.603-0.736   | <0.001 | ≥22.4   | 62.8            | 67.7            | 67.7    | 67.7    | 67.7  | 0.305            |
| Malignant-benign distinction | 0.651     | 0.584-0.718   | <0.001 | ≥23.79  | 61              | 59.6            | 59.6    | 59.6    | 59.6  | 0.205            |

NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-lymphocyte ratio; AUC: Area under the curve; CI: Confidence interval; PPV: Positive predictive value; NPV: Negative predictive value; +LHR: Positive Likelihood Ratio.

**FIGURE 1.** ROC curves showing malignant-control distinction for the NLR and PLR.

**FIGURE 2.** ROC curves showing malignant-benign distinction for the NLR and PLR.

ROC: Receiver operating characteristics; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio.
was 2.17 (sensitivity=64.1%, specificity=72%) and the significant cut-off value for PLR was 138.2 (sensitivity=60.9%, specificity=60.7%). To distinguish malignant patients from the benign group, a cut-off value of 2.24 for NLR (sensitivity=62.8%, specificity=67.7%) and a cut-off value of 137.9 for PLR (sensitivity=61%, specificity=59.6%) were used.

**DISCUSSION**

In the present study, we investigated the utility of markers such as NLR and PLR in detecting the presence of benign and malignant soft tissue tumors located in the extremities. None of these markers contributed to the detection of the presence of benign tumors, while both markers could detect the presence of malignant tumors separately. In addition, there was a significant difference in the NLR and PLR in differentiating malignant tumor from benign tumor. To the best of our knowledge, this study is the first to report the use of PLR in the diagnosis of STS. In addition, we observed that the total cholesterol, albumin, and EF levels of the patients in the malignant group were significantly lower than the patients in the benign group. In recent years, publications on the use of preoperative blood values and rates in determining the presence of sarcoma and prognosis have been increasing. Values such as neutrophil, lymphocyte, platelet, NLR, PLR, albumin, and total cholesterol are low-cost and easily applicable methods in all patients for routine follow-up before surgery. Recently, Arıkan et al.[13] reported that mean platelet volume (MPV) and MPV/platelet ratio are useful in the diagnosis of STS, but did not contribute to the prediction of the prognosis.[13]

In recent years, for the approach to benign and malignant tumors, systemic inflammatory biomarkers such as NLR and PLR have emerged as valid alternatives to traditional methods that have been shown to be associated with diagnosis and/or prognosis in different tumor types.[6-8] These ratios are easily obtainable values obtained from routine complete blood count without additional economic burden.

Studies examining the contribution of NLR in predicting the prognosis of STS are available in the literature. Recently, Idowu et al.[14] examined the contribution of this ratio to the diagnosis. They retrospectively analyzed the pre-treatment NLR of 223 patients with benign and malignant soft tissue tumors and considered NLR greater than 5 high, as described previous studies. They found NLR to be significantly higher in patients with malignant tumors compared to patients with benign tumors. In the current study, we compared the NLR of sarcomas with both benign tumors and the control group and found significantly higher than both groups. We also went a step further and separately obtained cut-off values for NLR in the differential diagnosis of patients with extremity sarcoma from patients without tumors and from patients with benign tumors.

To the best of our knowledge, there are studies examining the contribution of PLR to the prediction of the prognosis of STS; however, there is no study examining its contribution to the diagnosis. Therefore, this study is the first to report that PLR is a diagnostic marker. Que et al.[15] showed that both NLR and PLR were prognostic in STS and reported that PLR was superior to NLR in predicting prognosis. In the current study, we found that PLR was significantly higher in STS compared to benign tumors and control group. In addition, the cut-off value was obtained for the PLR ratio in the differential diagnosis of malignancy.

The process of membrane biogenesis in neoplastic diseases requires large amounts of lipids, including total cholesterol, lipoproteins and triglycerides.[16] Previous studies have suggested that abnormal lipid profiles may be associated with the development and progression of cancers.[15] In the current study examining soft tissue tumors located in the extremities, total cholesterol levels were found to be significantly lower in patients with sarcoma compared to patients with benign tumors or in the control group, consistent with these findings.

Many studies of sarcomas have focused on the cardiac effects of chemotherapeutic agents, emphasizing the importance of cardiac risk factors and baseline cardiac evaluations.[17] The necessity of cardioprotective treatments before chemotherapy and treatment methods are among the current issues. However, as far as we know, it has not been shown previously that preoperative EF values are lower in patients with sarcoma than healthy individuals. These results may raise the issue that these patients may have low baseline cardiac parameters and preventive measures may be taken before potential surgical treatments and chemotherapies that may have cardiac side effects.

In the present study, pre-treatment albumin levels of sarcomas were found to be significantly lower than those with benign tumors and the control group. Barreto-Andrade et al.[18] also found that albumin was prognostic in STS. It is evident that there is a need for larger studies investigating the
contribution of albumin value to diagnosis and screening in STSs.

This study has some limitations. It has a single-center, retrospective design with a relatively small sample size, primarily due to the rarity of tumoral diseases. We believe that future multi-center studies with larger sample sizes would further investigate the characteristics of inflammation and the role of systemic inflammatory biomarkers in soft tissue tumors of the extremity. On the other hand, the current study has several strengths. First, indicators of infection were evaluated and the effects of infection on inflammatory markers were prevented by excluding patients who were thought to be infected. Second, the diagnostic values of both inflammatory markers were evaluated and cut-off values were determined for both separately. These findings indicate that clinicians should pay attention to high NLR and PLR in the diagnosis of soft tissue masses with suspected malignancy. The NLR and PLR are easy to measure with simple, low-cost, widely used, and standardized tests.

In conclusion, NLR and PLR have a diagnostic value in extremity malignant soft tissue tumors. However, our results do not support the use of NLR and PLR as diagnostic purposes for benign soft tissue tumors. In addition, total cholesterol, albumin, and EF values are lower than normal in malignant soft tissue tumors located in the extremities. Further studies are warranted to draw more reliable conclusions on this subject.

Declaration of conflicting interests
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding
The authors received no financial support for the research and/or authorship of this article.

REFERENCES
1. Öztürk R, Arıkan ŞM, Bulut EK, Kekeç AF, Çelebi F, Güngör BŞ. Distribution and evaluation of bone and soft tissue tumors operated in a tertiary care center. Acta Orthop Traumatol Turc 2019;53:189-94.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
3. Morii T, Kishino T, Shimamori N, Motohashi M, Ohnishi H, Honya K, et al. Differential diagnosis between benign and malignant soft tissue tumors utilizing ultrasound parameters. J Med Ultrason (2001) 2018;45:113-9.
4. Grimer R, Judson I, Peake D, Seddon B. Guidelines for the management of soft tissue sarcomas. Sarcoma 2010;2010:506182.
5. Zhang Y, Yue B, Zhao X, Chen H, Sun L, Zhang X, et al. Benign or malignant characterization of soft-tissue tumors by using semiquantitative and quantitative parameters of dynamic contrast-enhanced magnetic resonance imaging. Can Assoc Radiol J 2020;71:92-9.
6. Liang Y, Wang W, Li J, Guan Y, Que Y, Xiao W, et al. Combined use of the neutrophil-lymphocyte and platelet-lymphocyte ratios as a prognostic predictor in patients with operable soft tissue sarcoma. J Cancer 2018;9:2132-9.
7. Liu G, Ke LC, Sun SR. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in patients with soft tissue sarcoma: A meta-analysis. Medicine (Baltimore) 2018;97:e12176.
8. Szkandera J, Absenger G, Liegl-Atzwanger B, Pichler M, Stotz M, Samonigg H, et al. Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients. Br J Cancer 2013;108:677-83.
9. Atik OŞ. Is there something new and interesting in my article? Eklem Hastalik Cerrahisi 2019;30:69.
10. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-98.
11. Böhning D, Holling H, Patilea V. A limitation of the diagnostic-odds ratio in determining an optimal cut-off value for a continuous diagnostic test. Stat Methods Med Res 2011;20:541-50.
12. Zogheib E, Cosse C, Sabbagh C, Marx S, Caus T, Henry M, et al. Biological scoring system for early prediction of acute bowel ischemia after cardiac surgery: The PALM score. Ann Intensive Care 2018;8:46.
13. Arıkan ŞM, Yapar A, Atalay İB, Toğral G, Pervane A, Güngör BŞ. Diagnostic and prognostic role of mean platelet volume and mean platelet volume/platelet ratio in the most common soft tissue sarcomas. Jt Dis Relat Surg 2021;32:204-9.
14. Idowu OK, Ding Q, Taktak AF, Chandrasekar CR, Yin Q. Clinical implication of pretreatment neutrophil to lymphocyte ratio in soft tissue sarcoma. Biomarkers 2012;17:539-44.
15. Que Y, Jiang F, Liu L, Li Y, Chen Y, Qiu H, et al. Clinical significance of preoperative serum high density lipoprotein cholesterol levels in soft tissue sarcoma. Medicine (Baltimore) 2015;94:e844.
16. Silvente-Poirot S, Poirot M. Cancer. Cholesterol and cancer, in the balance. Science 2014;343:1445-6.
17. Shamai S, Rozenbaum Z, Merimsky O, Derakhshesh M, Moshkovits Y, Arnold J, et al. Cardio-toxicity among patients with sarcoma: A cardio-oncology registry. BMC Cancer 2020;20:609.
18. Barreto-Andrade JC, Medina-Franco H. Serum albumin is an independent prognostic factor for survival in soft tissue sarcomas. Rev Invest Clin 2009;61:198-204.